Novartis Halts Rap-cel Trials After Three Patient Deaths

Three fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) have forced Novartis to suspend autoimmune and neurology trials of rapcabtagene autoleucel (rap-cel), raising immediate questions about process controls, patient monitoring protocols, and whether rapid manufacturing timelines are compressing the safety margins that GMP oversight is designed to protect.

The suspension covers the phase 2 AUTOGRAPH studies evaluating rap-cel in systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies (NCT06665256), along with phase 1/2 trials in rheumatoid arthritis, Sjogren disease (NCT07048197), generalized myasthenia gravis, and certain multiple sclerosis subtypes. Oncology studies of rap-cel remain active. Novartis confirmed it is working with independent data monitoring committees to implement enhanced safety measures, including tighter patient monitoring, earlier adverse event identification, and improved management strategies.

Bristol Myers Squibb separately paused at least some studies of zolacabtagene autoleucel (zola-cel) across its autoimmune program, spanning myasthenia gravis, multiple sclerosis, and rheumatoid arthritis, describing the action as precautionary following observation of transient and reversible inflammatory events. No deaths have been linked to zola-cel; a single prior IEC-HS case was reported in February phase 1 data. BMS characterised the therapy's safety profile as consistent with the known profile of CAR-T therapies.

For QA directors and process development leads, the manufacturing angle warrants close attention. Analysts at William Blair identified rapid manufacturing, a feature shared by both rap-cel and zola-cel, as a possible contributor to the observed toxicities, noting that accelerated production could drive increased cell expansion and heightened inflammatory potential. Indication-specific factors and patient predisposition to hyperinflammatory states were also cited as variables that remain difficult to isolate at this stage of development.

IEC-HS is not a novel risk category; it has been documented previously with CD19- and BCMA-directed CAR-T therapies in haematologic oncology. Its emergence in autoimmune populations, where patient immune baselines differ substantially from oncology cohorts, signals that existing risk mitigation frameworks may need recalibration before these programs scale. Competing CD19-directed autoimmune CAR-T developers, including Autolus, Cabaletta Bio, CRISPR Therapeutics, Kyverna Therapeutics, and Allogene Therapeutics, will face intensified scrutiny of their own manufacturing and safety monitoring designs as regulators and sponsors assess whether the signals observed here are platform-wide or program-specific.

The outcome of Novartis's safety data review, and the scope of any protocol amendments filed with regulators, will serve as a reference point for how the broader autoimmune CAR-T field calibrates its GMP oversight and patient safety monitoring going forward.

Source: CGTLive via cgtlive.com, 2 September 2026.